Sandbox Reserved 1713: Difference between revisions
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
<scene name='90/904318/Alkalbindingsurfacewmembrane/1'>Binding surface of ALKAL with the membrane</scene> | <scene name='90/904318/Alkalbindingsurfacewmembrane/1'>Binding surface of ALKAL with the membrane</scene> | ||
<scene name='90/904318/Alkal1membraneinteraction/2'>ALKAL's residues that interact with membrane</scene> | <scene name='90/904318/Alkal1membraneinteraction/2'>ALKAL's residues that interact with membrane</scene> | ||
===Conformational Change=== | |||
In order for the Anaplastic Lymphoma Kinase (ALK) to move across the membrane to bind with the second monomer, it has to undergo a conformational change. The Anaplastic Lymphoma Kinase Activating Ligand (ALKAL) binds to the binding surface on the ALK. This induces a conformational change which allows for the PXL and the GlyR domains to hinge forward. <ref>DOI: 10.1038/s41586-021-04140-8</ref> The kinase is now ready to move across the membrane and attach to the other kinase to be fully activated. | |||
== Disease == | == Disease == | ||
<scene name='90/904318/Premutationresidues/1'>residues that are mutated</scene> | <scene name='90/904318/Premutationresidues/1'>residues that are mutated</scene> | ||
== Relevance == | == Relevance == | ||
== Structural highlights == | == Structural highlights == | ||